NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Bicycle Therapeutics PLC BCYC
9 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 72.6M
Revenue, FY2025 · full 9-year series below
Revenue $M
Net income $M
FY2025 · Revenue 72.6 · Net income -219.0
Compound annual growth
Revenue compounded at +47.5% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−302 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -340.4% · Net -301.7%
ROE
FY2025 · ROE -31.2%
Each USD of equity lost 31 cents this year.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Net income $B | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.3 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −3.16 | −2.90 | −5.08 | −3.80 | −2.67 | −2.66 | −2.77 | −49.78 | −48.81 |
| Dividend / sh $ | 0.00 | 0.00 | 0.00 | 0.00 | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | −31.2 | −29.0 | −56.3 | −36.5 | −30.3 | −54.1 | −261.9 | · | · |
| Shares out B | 0.07 | 0.07 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 34 reconciliationsAUDITED
Reconciled in 9 of 19 fiscal years. 42 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017